23:39 , Aug 9, 2019 |  BC Extra  |  Company News

Enbrel ruling lifts Amgen shares

A decision by the U.S. District Court for the District of New Jersey late Friday removed a key overhang on Amgen shares when it upheld two Enbrel patents at stake in a suit against Sandoz....
15:47 , Mar 28, 2019 |  BioCentury  |  Product Development

Contracting practices limiting U.S. biosimilars uptake

The U.S. biosimilars market lags Europe’s and won’t catch up until physicians understand and become comfortable with the concept of similarity, Sheila Frame, who heads up Sandoz’s North American biosimilars business, told BioCentury. To create...
17:33 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
20:37 , Jul 19, 2018 |  BC Extra  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos...
23:52 , Feb 9, 2018 |  BC Extra  |  Politics & Policy

American College of Rheumatology recommends biosimilars for rheumatic disease

In a white paper published in Arthritis & Rheumatology , the American College of Rheumatology now recommends the use of biosimilars to treat rheumatic disease, saying they should be incorporated into the U.S. healthcare system....
01:38 , Jan 3, 2018 |  BC Extra  |  Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report. Allergan spokesperson Mark Marmur told BioCentury...
00:40 , Jan 10, 2017 |  BC Extra  |  Company News

Novartis' Jimenez gives biosimilar update

At the JPMorgan Healthcare Conference on Monday, Novartis AG (NYSE:NVS; SIX:NOVN) CEO Joe Jimenez outlined the pharma's commercial strategy for new and upcoming biosimilars, and discussed the company's expectations of price erosion for biosimilars. Jimenez...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
20:00 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

Erelzi: Additional Ph III EGALITY data

Additional data from the switching portion of the double-blind, international Phase III EGALITY trial showed no clinically meaningful differences in safety and efficacy in patients who alternated between treatment with Erelzi and Enbrel etanercept. The...
23:41 , Nov 22, 2016 |  BC Extra  |  Clinical News

Sandoz: Biosimilar matches Enbrel in switching study

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said there were "no clinically meaningful differences" between the safety or efficacy of its biosimilar Erelzi etanercept-szzs and reference product Enbrel etanercept after 52 weeks in the...